Shares of Intersect ENT Inc. (NASDAQ:XENT) were down 1.9% during trading on Friday . The stock traded as low as $15.24 and last traded at $15.51, with a volume of 77,820 shares. The stock had previously closed at $15.81.

Several analysts have commented on XENT shares. BTIG Research restated a “hold” rating and issued a $14.00 price objective on shares of Intersect ENT in a report on Thursday, August 4th. Wedbush restated an “outperform” rating and issued a $25.00 price objective on shares of Intersect ENT in a report on Monday, July 18th. Zacks Investment Research upgraded shares of Intersect ENT from a “sell” rating to a “hold” rating in a report on Wednesday, May 11th. Canaccord Genuity restated a “buy” rating on shares of Intersect ENT in a report on Monday, July 18th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $21.00 price objective on shares of Intersect ENT in a report on Friday. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $24.00.

The firm has a 50-day moving average price of $14.95 and a 200 day moving average price of $15.96. The stock’s market capitalization is $444.74 million.

Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.05. During the same quarter in the previous year, the company posted ($0.23) earnings per share. The firm had revenue of $19.30 million for the quarter, compared to the consensus estimate of $18.91 million. The business’s revenue for the quarter was up 27.0% on a year-over-year basis. Equities research analysts anticipate that Intersect ENT Inc. will post ($0.96) earnings per share for the current year.

In related news, VP James Stambaugh sold 5,000 shares of the company’s stock in a transaction dated Monday, July 18th. The shares were sold at an average price of $15.33, for a total transaction of $76,650.00. Following the transaction, the vice president now directly owns 29,000 shares in the company, valued at approximately $444,570. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

A hedge fund recently raised its stake in Intersect ENT stock. RS Investment Management Co. LLC boosted its stake in shares of Intersect ENT Inc. (NASDAQ:XENT) by 68.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,328,250 shares of the company’s stock after buying an additional 538,720 shares during the period. RS Investment Management Co. LLC owned approximately 4.74% of Intersect ENT worth $29,886,000 as of its most recent filing with the SEC.

Intersect ENT, Inc is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.